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Background/Aims: Interval gastric cancer (IGC) is defined 
as cancer that is diagnosed between the time of screening 
and postscreening esophagogastroduodenoscopy (EGD). Un-
fortunately, little is known about the characteristics of IGC in 
Korea, a country with a high incidence of gastric cancer. The 
aim of this study was to evaluate the clinicopathologic char-
acteristics of IGCs in Korea. Methods: From January 2006 to 
July 2011, a total of 81,762 subjects underwent screening 
EGD at Yonsei University Health Promotion Center, Seoul, Ko-
rea. We defined missed cancer as cancer diagnosed within 
1 year of screening EGD and latent cancer as cancer diag-
nosed more than 1 year after EGD. Results: A total of 16 IGC 
patients (17 lesions; three missed cancers and 14 latent can-
cers) were identified, with a mean age of 60.68 years and 
a mean interval time of 19.64 months. IGCs tended to be 
undifferentiated (12/17, 70.6%), located in the lower body 
of the stomach (12/17, 70.6%) and exhibited flat/depressed 
endoscopic morphology (11/17, 64.7%). The patients with 
missed cancer were generally younger than the patients 
with latent cancer (51.3 years vs 62.8 years, p=0.037), and 
the patients with undifferentiated cancer were significantly 
younger than those with differentiated cancer (57.0 years vs 
68.8 years, p=0.008). Conclusions: IGCs tended to be undif-
ferentiated, located in the lower body of the stomach, and 
exhibited flat/depressed endoscopic morphology. (Gut Liver, 
2015;9:167-173)
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INTRODUCTION
Gastric cancer is one of the most common cancers worldwide, 
with approximately 989,600 new cases and 738,000 deaths 
per year.1 Gastric cancer incidence rates are highest in Eastern 
Europe, South America, and Eastern Asia, especially in China, 
Japan, and Korea.2,3 However, mortalities associated with gastric 
cancer have decreased remarkably in Asian countries in recent 
years, potentially due to healthcare policies that have introduced 
screening tests for the early detection of gastric cancer.4 Early 
detection of gastric cancer is important because the prognosis of 
early gastric cancer is highly favorable.5,6 For this reason, esoph-
agogastroduodenoscopy (EGD), the diagnostic tool of choice for 
detecting gastric cancer, has been widely conducted as a part of 
health checkups in recent years. 
In Korea, national gastric cancer screening was instituted in 
1999 as part of the National Cancer Screening Program (NCSP). 
The NCSP recommends biennial gastric cancer screening for 
males and females older than 40 years of age, using direct or 
indirect upper gastrointestinal series (UGIS) or EGD.7 However, 
there is a debate about the quality of screening EGD and ap-
propriate screening intervals, leading to the concept of interval 
cancer. 
Interval cancer is defined as cancer that is diagnosed between 
the time of screening and postscreening endoscopy.8 Consider-
ing colorectal cancer, some consensus and quality indicators 
have recently been established,8,9 and show that improvements 
in the quality of colonoscopy may have reduced cancer preva-
lence or resulted in earlier cancer detection in over 50% of 
prevalent cancers.9 However, little is known about the charac-
teristics, incidence, and cause of interval gastric cancer (IGC), 
especially in a country with a high gastric cancer incidence. 
In this study, we assessed the performance of endoscopic sur-
veillance screening at a single qualified institute. The aim of this 
See editorial on page 133.
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study was to evaluate the clinicopathologic characteristics of 
IGC in Korea and to propose quality indicators for EGD screen-
ing. 
MATERIALS AND METHODS
1. Study population
Gastric cancer screening data was obtained from the Yonsei 
University Health Promotion Center, Seoul, Korea from January 
2006 to July 2011. The database included patients’ demographic 
characteristics and screening EGD results, used for retrospective 
analysis. We selected patients who were diagnosed with gastric 
cancer following a previously-performed screening EGD at the 
same center. The control group is recruited as who underwent 
screening EGD on the same day with IGC patients at the same 
center with twice the number of patients. We did not conduct 
age- and sex-matching for recruiting control group because to 
compare clinicopathologic characteristics of IGC patients and 
control group, which included age and sex, we randomly re-
cruited control group who underwent screening EGD just before 
and after IGC patients by the same endoscopist. 
The exclusion criteria were as follows: no previous history 
of screening EGD; previous history of screening EGD at outside 
our institute because we could not determine the exact results 
of screening EGD; and previous history of gastric cancer. 
The study was performed in accordance with the ethical 
guidelines of the 1975 Declaration of Helsinki. Written informed 
consent was obtained from each participant or responsible fam-
ily member after possible complications of the diagnostic proce-
dures had been fully explained. This study was approved by the 
Institutional Review Board of Yonsei University.
2. Esophagogastroduodenoscopy
All EGDs were performed with a standard single-channel en-
doscope (GIF-Q260 or GIF-H260; Olympus Optical Co., Ltd., To-
kyo, Japan). All six endoscopists were trained at single tertiary 
medical center before working at our institute and all of them 
were board-certified.
3. Definitions and clinical analysis
IGC is defined as gastric cancer which diagnosed between the 
time of screening and postscreening EGD at the same center. 
Missed cancer is defined as that diagnosed within 1 year of 
screening EGD and latent cancer as that diagnosed more than 
1 year after screening EGD, based on a previous study.10 The 
following data were collected: demographic characteristics of 
study population, interval time between the time of diagnosis 
and screening EGD, cancer histology, and endoscopic findings. 
We analyzed the IGC rate and the clinicopathologic charac-
teristics of IGCs. We compared IGC patients and control group 
and compared latent and missed cancer. Additionally, compar-
ing differentiated cancer with undifferentiated cancer based on 
histologic finding.
4. Statistical analysis
Descriptive data are presented as the percentage of patients 
or as the mean±standard deviation. The cumulative incidence 
rate of IGCs was calculated as the number of IGCs diagnosed 
per 10,000 endoscopic examinations. A chi-square test or Fisher 
exact test for categorical variables and an independent sample 
t-test or Mann-Whitney U-test for continuous variables was 
used. To compare continuous variables among groups, one-way 
analysis of variance (ANOVA) was used as appropriate. SPSS 
version 18.0 software (SPSS Inc., Chicago, IL, USA) was used for 
all statistical analyses. A p-value <0.05 on a two-tailed test was 
considered statistically significant.
RESULTS
1. Study population characteristics
During the study period, 81,762 subjects underwent EGD at 
our institute. Among them, 112 patients were diagnosed with 
gastric cancer. Of these, 96 patients were excluded according 
to our exclusion criteria. Finally, a total of 16 IGC patients (17 
Fig. 1. Flowchart of enrolled pa-
tients. A total of 81,762 subjects un-
derwent esophagogastroduodenos-
copy (EGD) at our institute. Among 
them, 112 patients were diagnosed 
with gastric cancer. Of these, 96 
patients were excluded according to 
our exclusion criteria. Finally, a total 
of 16 patients diagnosed interval 
gastric cancer.
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lesions) were identified (Fig. 1), 15 of 17 lesions were diagnosed 
as EGC and two of 17 as advanced gastric cancer (AGC).
Clinicopathologic characteristics of 16 patients (eight male) 
who diagnosed IGC are described in Table 1. The mean age was 
60.68 years, and the mean interval time between the time of 
diagnosis and screening EGD was 19.64 months. One of IGC 
patient’s screening and postscreening EGD are shown (Fig. 2). 
IGCs tended to be undifferentiated type (12/17, 70.6%), located 
in lower body of stomach (12/17, 70.6%), and have flat/de-
pressed endoscopic morphology (11/17, 64.7%). The cumulative 
incidence rate IGCs was 2.07 per 10,000 patients, and most IGCs 
were detected at 12 to 18 months after screening EGD (Fig. 3).
2. Comparison with control group
In comparison with the control group, the IGC patients was 
significantly older (mean age, 60.7 years vs 53.5 years, p=0.033) 
(Table 2). There were no statistically significant differences 
about previous history of gastric ulcer, previous history of He-
licobacter pylori infection, smoking status, alcohol ingestion, 
and family history of gastric cancer between two groups. In the 
screening EGD, a finding of atrophic gastritis was significantly 
frequent in the IGC patients than in the control group (52.9% 
vs 9.4%, p=0.001) but there were no significant differences in 
findings of intestinal metaplasia (IM), single erosion, and biopsy 
frequency. 
3. Previous situation of IGC lesion
The previous situation of 17 IGC lesions based on their 
screening EGD results was described at Supplementary Table 1. 
Two lesions were atrophic gastritis and five were superficial gas-
tritis without focal lesion. Three lesions were combined atrophic 
gastritis and diffuse IM. One lesion was combined atrophic gas-
tritis and diffuse erosions and one lesion was combined atrophic 
gastritis and single erosion with pathologically confirmed. Two 
lesions were combined with atrophic gastritis with polypoid le-
sion, and IM was confirmed pathologically both of them. One 
lesion was combined with superficial gastritis and diffuse ero-
sions, two lesions were combined superficial gastritis and single 
erosion, both of them pathologically confirmed with erosion.
4. Comparison with latent cancer and missed cancer
Among 17 lesions of IGC, three lesions (three patients) were 
missed cancers and 14 lesions (13 patients) were latent cancers. 
Patients with missed cancers were significantly younger than 
those with latent cancers (mean age, 51.3 years vs 62.8 years; 
p=0.037), and although statistically not significant, latent can-
cer tended to more AGC than missed cancer (14.3% vs 0%, 
p>0.005) (Table 3). All missed cancers were undifferentiated 
Table 1. Clinicopathologic Characteristics of the Interval Gastric Can-
cer Group (n=16)
              Characteristic Value
Age, yr 60.68±8.84
Male sex 8 (50.0)
Early gastric cancer 15/17 (88.2)
Advanced gastric cancer 2/17 (11.8)
Interval time, mo 19.64±7.51
Macroscopic morphology
   Elevated 6/17 (35.3)
   Flat 5/17 (29.4)
   Depressed 6/17 (35.3)
Location I
   Lower body 12/17 (70.6)
   Mid body 3/17 (17.6)
   Upper body 2/17 (11.8)
   Antrum 0/17
Location II
   Anterior wall 4/17 (23.6)
   Posterior wall 5/17 (29.4)
   Lesser curvature 3/17 (17.6)
   Greater curvature 5/17 (29.4)
Pathology
   Differentiated 5/17 (29.4)
   Undifferentiated 12/17 (70.6)
Data are presented as mean±SD or number (%).
Fig. 2. Esophagogastroduodenoscopy 
(EGD) of an interval gastric cancer 
patient. A 50-year-old female’s EGD 
at screening (A) and postscreening 
(B). Screening EGD finding was dif-
fusely mild atrophic gastritis without 
focal lesion. However, after 15.6 
months, early gastric cancer at the 
lower body, anterior wall of the 
stomach was diagnosed. Pathology 
was reported as signet ring cell car-
cinoma.
A B
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type and 66.7% (2 of 3) lesions showed depressive endoscopic 
morphology.
5. Comparison with rapidly growing cancer and slowly 
growing cancer
We further analyzed 17 IGC lesions as rapidly growing cancer 
and slowly growing cancer, according to interval time of 24 
months which recommends by Korean NCSP7 (Supplementary 
Table 2). Five lesions (four patients) were slowly growing can-
cers and 12 lesions (12 patients) were rapidly growing cancers. 
Patients with rapidly growing cancer were tended to younger 
than those with slowly growing cancer without statistical sig-
nificance (mean age, 58.7 years vs 66.2 years; p>0.05). There 
were no significant different in proportion of AGC, macroscopic 
morphology of cancer, location of cancer, and pathology in 
both two groups. 
Fig. 3. Cumulative incidence of interval gastric cancer and interval 
time. The cumulative incidence rate of interval gastric cancer was 2.07 
per 10,000 patients, and most incidences of interval gastric cancer 
were detected at 12 to 18 months after screening esophagogastroduo-
denoscopy (EGD).
Table 2. Comparison with the Control Group
Interval cancer 
group (n=16)
Control group 
(n=32)
p-
value
Age, yr 60.68±8.84 53.53±7.08 0.033
Male sex 8 (50.0) 18 (56.3) NS
Previous history of  
gastric surgery
0 0 NS
Previous history of  
gastric ulcer
2 (12.5) 3 (9.4) NS
Previous history of  
H. pylori infection
4 (25.0) 7 (21.9) NS
Smoking status NS
   Current 2 (12.5) 2 (6.3)
   Ex 3 (18.8) 8 (25.0)
   None 11 (68.7) 22 (68.7)
Alcohol ingestion* 2 (12.5) 5 (15.6) NS
Family history of  
gastric cancer
2 (12.5) 3 (9.4) NS
Interval time, mo 19.64±7.51 20.93±8.71 NS
Screening EGD
   Procedure time, sec 237±54.24 231.84±88.01 NS
   Atrophic gastritis 9 (52.9)† 3 (9.4) 0.001
   Intestinal metaplasia 3 (17.6)† 5 (15.6) NS
   Single erosion 3 (17.6)† 4 (12.5) NS
   Biopsy frequency 1.46±1.89 1.04±1.55 NS
Data are presented as mean±SD or number (%).
NS, not significant; H. pylori, Helicobacter pylori; EGD, esophagogas-
troduodenoscopy.
*Alcohol ingestion in excess of 40 g/day for more than 3 years; †% 
was calculated based on the number of lesions (n=17).
Table 3. Comparison with Latent Cancer and Missed Cancer
Latent cancer Missed cancer
p-
value
Patient number (lesion) 13 (14) 3 (3)
Age, yr 62.84±7.55 51.33±9.07 0.037
Male sex 6 (46.2) 2 (66.7) NS
Interval time, mo 21.53±7.01 11.67±0.57 0.001
Early gastric cancer 11 (84.6) 3 (100.0) NS
Advanced gastric cancer 2 (15.4) 0
Macroscopic morphology NS
   Elevated 5 (35.7) 1 (33.3)
   Flat 5 (35.7) 0
   Depressed 4 (28.6) 2 (66.7)
Location I NS
   Lower body 10 (71.4) 2 (66.7)
   Mid body 2 (14.3) 1 (33.3)
   Upper body 2 (14.3) 0
   Antrum 0 0
Location II NS
   Anterior wall 3 (21.4) 1 (33.3)
   Posterior wall 5 (35.7) 0
   Lesser curvature 2 (14.3) 1 (33.3)
   Greater curvature 4 (28.6) 1 (33.3)
Pathology NS
   Differentiated 5 (35.7) 0
   Undifferentiated 9 (64.3) 3 (100.0)
Data are presented as mean±SD or number (%).
NS, not significant.
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6. Comparison with differentiated cancer and undifferenti-
ated cancer
Based on histologic finding, 12 lesions were reported as un-
differentiated cancer (11 patients) and five lesions (five patients) 
as differentiated cancer. Patients with undifferentiated cancer 
were significantly younger than patients with differentiated 
cancer (mean age, 57.0 years vs 68.8 years; p=0.008) (Table 4). 
Although statistically not significant, the mean interval time 
tended to be shorter in patients with undifferentiated cancer 
than in those with differentiated cancer (18.71 months vs 21.25 
months, p>0.005).
7. Oncologic outcome of IGC patients
Among of 16 IGC patients, two patients were lost to follow-
up due to referral to outside institute at the time of cancer diag-
nosis. Among of 14 patients who treated and followed, five pa-
tients treated with endoscopic submucosal dissection and nine 
patients with gastrectomy. Thirteen patients (92.9%) have lived 
with no disease recurrence until December 2013 (mean follow-
up duration, 37.0 months), only one patient (7.1%) experienced 
disease recurrence after gastrectomy with peritoneal seeding 
and now on chemotherapy. This patient’s interval time was 33.4 
months and cancer histology was signet ring cell carcinoma. 
DISCUSSION
Screening EGD can be helpful for the early detection of 
gastric cancer. However, an optimal interval between screen-
ing tests has not been established due to the limited number of 
studies in this field.
In studies conducted in Japan, Shiratori et al.11 reported that 
a 1.5-year interval between screenings was sufficient to detect 
EGC. Mori et al.12 concluded that a 2-year screening interval 
was sufficient to increase the survival rate in gastric cancer. In 
Korean studies, Nam et al.13 showed that a 2-year endoscopic 
screening interval was helpful for detecting gastric cancers that 
warranted endoscopic resection. Lee et al.14 demonstrated that a 
maximal screening interval of 3 years is required to detect EGC 
in patients without IM, and a 2-year screening interval is rec-
ommended for patients with IM. 
The Korean NCSP recommends biennial screening UGIS or 
EGD for older than 40 years of age.7 However, in this study, 
the mean interval time for IGCs was 19.64 months and most 
IGCs were detected at 12 to 18 months after screening, which 
is shorter than the 2-year interval recommended by the Korean 
NCSP. Additionally, especially in patients with undifferenti-
ated cancer, which has poor prognosis,15,16 the interval time was 
shorter than those for patients with differentiated cancer. Over-
all, these results do not support the use of this 2-year guideline, 
and we are proposing reconsideration of the appropriateness of 
the 2-year screening interval. 
Interval cancers can occur as a result of the failure to detect 
a mucosal abnormality at the time of screening or as a new 
event after a negative screening.17 Based on the gastric cancer 
doubling time of approximately 2 to 3 years18 and a mean inter-
val time of 19.64 months of this study, IGCs in this study were 
considered likely due to failure of the screening EGD to detect 
an abnormality. And IGCs tended to exhibit flat/depressed 
endoscopic morphology (11/17, 64.7%). The accuracy of endo-
scopic procedure is directly influenced by the skill of the en-
doscopists and/or the quality of endoscopic video systems and 
videoscope.19-21 To detect cancers with flat/depressed endoscopic 
morphology and to prevent failed attempts to detect a mucosal 
abnormality, the use of high-definition endoscopy equipment 
and performance of endoscopy by expert endoscopists are im-
portant.
This study utilized data obtained at a single qualified institute 
with similar quality of endoscopic video systems/videoscope 
and similary-trained endoscopists. The incidence rate of IGC in 
this study was 2.07/10,000 as single qualified institute is mean-
ingful in comparison of previously reported national institute 
data of that 1.25/1,000 with missed cancer in the first round 
and 1.11/1,000 in the subsequent round.22 We think the reason 
of low miss rate in this study than previous study is due to 
Table 4. Comparison with Differentiated Cancer and Undifferentiated 
Cancer
Undifferentiated 
cancer
Differentiated 
cancer
p-value
Patient number (lesion) 11 (12) 5 (5)
Age, yr 57.0±7.88 68.8±4.26 0.008
Male sex 6 (54.5) 2 (40.0) NS
Interval time, mo 18.71±7.76 21.25±7.25 NS
Early gastric cancer 11 (91.7) 4 (80.0) NS
Advanced gastric cancer 1 (8.3) 1 (20.0)
Macroscopic morphology NS
   Elevated 4 (33.3) 2 (40.0)
   Flat 4 (33.3) 1 (20.0)
   Depressed 4 (33.3) 2 (40.0)
Location I NS
   Lower body 8 (66.7) 4 (80.0)
   Mid body 3 (25.0) 0
   Upper body 1 (8.3) 1 (20.0)
   Antrum 0 0
Location II NS
   Anterior wall 4 (33.3) 0
   Posterior wall 2 (16.7) 3 (60.0)
   Lesser curvature 2 (16.7) 1 (20.0)
   Greater curvature 4 (33.3) 1 (20.0)
Data are presented as mean±SD or number (%).
NS, not significant.
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qualified endoscopic device and endoscopist control of single 
institute. These results suggest the importance of standard-
ized endoscopic video systems/videoscope and quality control 
among endoscopists in screening EGD.
In consideration of atrophic gastritis as a premalignant con-
dition and the multifocal nature of the metaplastic process,23,24 
thorough endoscopic evaluation is usually needed.25,26 Kato 
et al.27 estimated that the risk of gastric cancer in individuals 
with atrophic gastritis was 25-fold for differentiated types and 
3.5-fold for undifferentiated types of cancer. In this study, IGC 
patients showed significantly higher proportions of atrophic 
gastritis than the control group in their previous screening EGDs 
(52.9% vs 9.4%, p=0.001). This result suggests that patients 
diagnosed with atrophic gastritis in a screening EGD should be 
closely followed in their next EGD which coincide with previous 
study.23
In this study, IGCs tended to be more undifferentiated type, 
which has a poorer prognosis.15,16 And patients with undiffer-
entiated type IGCs tended to be younger than those with dif-
ferentiated cancers. Patients with missed cancer were younger 
than those with latent cancer and all three missed cancers were 
the undifferentiated type. Considering the poorer prognosis and 
younger age, there results raise the importance of detecting 
IGCs and missed cancers, which should be considered risky, es-
pecially in younger patients.
This study has some limitations. First, the retrospective study 
design and small sample size could cause statistical error or 
include confounding factors. Even if IM is regarded as another 
premalignant condition of gastric cancer,23,24 there was no sig-
nificant difference finding of IM in screening EGD between the 
IGC patients and the control group. We think this might be due 
to small sample size. Second, selection bias in recruiting control 
group and IGC group who only underwent previous screening 
EGD at the same center and performed EGD by many endos-
copists, because endoscopic finding is interpreted subjectively 
by endosopist, could weaken strength of this study. Third, this 
study design utilized a single qualified institute, so endoscopy/
endoscopist quality variables could not be evaluated. Further 
prospective large-scale designed study is needed to suggest IGC-
related risk factors and provide endoscopy/endoscopist quality 
indicators to predict early cancers based on results from this 
study.
However, recent publications8,9 on assessing rates of colorec-
tal cancer missed during colonoscopy have generated efforts 
toward the improvement of colonoscopy quality, and this study 
could support that EGD quality control is important to enhance 
cancer detection rates and reduce IGC rates. We think the im-
portant factor for complete quality control of gastric cancer is 
endoscopy/endoscopist quality control.
In conclusion, IGCs tended to be undifferentiated, exhibit flat/
depressed endoscopic morphology, and located in the lower 
body of the stomach with shorter interval time than 2-year after 
screening EGD. The 2-year screening interval should be recon-
sidered and national endoscopy/endoscopist quality control is 
needed in diagnosing gastric cancers in Korea, a country with a 
high gastric cancer incidence.
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